Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Medical Tech Outlook
![]()
We are changing the status quo in the market with our unique Retinal Deep Phenotyping platform that is all set to change mindsets when it comes to brain health
Share this Article:
Tweet
|
Company
Optina Diagnostics
Headquarters
Montreal, Canada
Management
David Lapointe, CEO
Description
Optina’s Retinal Deep Phenotyping platform addresses the significant challenges faced by the healthcare system related to an ageing population. The company’s ecosystem comprises a proprietary platform, and a network of eye clinics creates a new and efficient means for simple patient stratification. The ecosystem allows for the collection of data-rich retinal images with thirty times more information than current retinal imaging platforms. Algorithm development utilizes a ground truth that is based on specifically characterized patients from leading institutions around the world. With it’s developing product pipeline, Optina continues to bring clarity and accessibility to early-stage diagnosis, improving the lives of millions
I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info